|
|
142 West 57th St #4A
New York, NY 10019 USA
phone:6465155424
fax:
|
|
| Symbol |
Private |
| Founded |
2005 |
| Employees |
2 |
|
|
| www.valam.com
|
|
|
|
 |
| Summary Description |
| Focused on providing laser-based infection and surgical therapies to otolaryngologists, and their patients worldwide. |
|
| Management |
| Dr. Yosef Krespi, Chairman of the Board and Chief Scientific Officer, CEO; David Elliot, former COO of TYRX, Inc., former CEO of Valam, Inc. and former President/COO of VistaCare, Inc.; Thomas Hardy, Chairman of the Board of the American University of Paris; Yacha Sutton, former CEO of ESC Medical and Lumenis |
| |
|
|
| |
|
| Keywords |
| laser-based therapeutics, otolaryngologist, surgical therapies otolaryngology, ear disorders, nose disorders, throat disorders, sinus disorders, Germany, New York |
|
|
|
| Description |
|
Founded in 2005 by Yosef Krespi, M.D., F.A.C.S., and incorporated in March 2006, Valam Corporation, a Delaware company, is focused on providing laser-based infection and surgical therapies to otolaryngologists, and their patients, worldwide. Otolaryngologists, also referred to as Ear, Nose and Throat doctors or “ENTs,” specialize in the diagnosis and treatment of ear, nose, throat, and sinus disorders. The Company is currently headquartered in New York, with additional technology development facilities in Germany. |
|
| Products / Services |
Nd:YAG Laser and 940nm Infrared Diode Laser Valam therapy WILL Via Shockwave Disrupt a majority of visible Biofilm Expose Biofilm protected (and therefore antibiotic resistant) bacteria to antimicrobial therapy, (IR and/or antibiotics) Via Near IR Laser Illumination (NILI) Decrease bacteria by a 2x to 3x log reduction (90%+ killing) Decrease frequency and dosage of antibiotics required Re-sensitize the resistant antibiotics Decrease frequency of MD office visits Improve the efficacy of FESS (sinus surgery), and reduce the need for a second surgical procedure Improve CRS patient outcomes and QOL
|
|
| Technology / Differentiation |
| Based on the clinical needs in the area of Chronic Rhino Sinusitis, CRS, Valam has chosen specific light wavelengths for optimum antibacterial and antifungal properties, and delivery methods that require no new skills for the endoscopically trained physician. Valams primary platform products are: Nd:YAG Laser delivers a high energy, short pulse that creates a cool shockwave perfectly suited to disrupt bacteria-generated biofilm. 940nm Infrared Diode Laser delivers a low energy, longer pulse of light that has been proven to kill bacteria and fungi. |
|
| Market / Customers |
Chronic Rhinosinusitis (CRS) Market -over 30 million patients diagnosed with CRS in the U.S. -at least 30 million courses of antibiotic therapies are prescribed each year for CRS, and rhinosinusitis accounts for 21% of all adult antibiotic prescriptions. -over 500,000 CRS patients, whose symptoms were not resolved by antibiotic and steroid therapy, undergo Functional Endoscopic Sinus Surgery (FESS). -recurrent CRS can occur in post-FESS patients as often as 30% of the time, resulting in the need for a second surgical intervention. -total direct U.S. health care expenditures due to CRS exceeded $8 billion in 2008, establishing rhinosinusitis as one of the most expensive disorders experienced by the US population.
|
|
| Competitors / Substitutes / Alternatives |
Lumenis anecdotal R&D efforts focused on antimicrobial lasers.
LumeRx - uses radiant energy from visible light to treat H. pylori.
Nomir a Valam partner in MRSA human feasibility testing, is developing optical therapeutic products for the treatment of bacterial and fungal infections and aesthetic diseases. Initial foci are periodontal disease, toe-nail fungus and MRSA.
Ondine Biopharma Corp. is developing its platform photo-activated disinfection (PAD) technology for three initial applications: periodontal diseases, methicillin-resistant Staphylococcus aureus and nail-bed fungal infections.
Acclarent, now a division of J&J Ethicon transnasal sinuplasty balloon procedure performed in the hospital setting under general anesthesia.
Entellus Medical upper gum line access sinuplasty balloon procedure performed in the physician office setting under local anesthesia.
|
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members